SELLAS Life Sciences (SLS) Receivables (2012 - 2022)

SELLAS Life Sciences (SLS) has reported Receivables for 5 consecutive years, with $1.0 million the latest figure, recorded in Q1 2022.

• In Q1 2022, Receivables changed N/A year-over-year to $1.0 million; the TTM figure through Mar 2022 stood at $1.0 million (changed N/A YoY), while the FY2014 annual figure was $1.8 million, down 50.07% from the prior year.
• Receivables retreated to $1.0 million in Q1 2022 per SLS's latest filing, from $1.8 million in the prior quarter.
• Across five years, Receivables topped out at $1.0 million in Q1 2022 and bottomed at $1.0 million in Q1 2022.